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1. Introduction 
Psoriasis is a chronic inflammatory skin disorder characterized by hyper-proliferation of 
basal keratinocytes, thickened and scaly epidermis, and recruitment of inflammatory cells to 
the skin. It affects approximately 2% of the world’s population. The disease follows a 
pathogenic pathway involving various immunocytes and immune molecules. Activated T 
cells have been shown to trigger a chain of cellular and molecular reactions leading to the 
formation of psoriatic lesions. Fusion proteins that can block T cell activation or the function 
of anergized T cells, and cytokines and biologics that can inhibit T cell migration are 
effective in the treatment of psoriasis. Intradermal injection of T cells from psoriatic patients 
into human skin/severe combined immunodeficient (SCID) mice can induce spontaneous 
psoriatic conversion of skins from healthy human or non-lesional skin from psoriatic 
patients. Thus, it is widely accepted that psoriasis is a T lymphocyte-mediated autoimmune 
disease. Although the roles of T cells in psoriasis have been confirmed, the exact 
mechanisms of psoriasis and the origin of abnormal T cells are still unclear.  
Beside T cells, psoriatic patients have a wide variety of other immune abnormalities such as 
B cells, monocytes, neutrophils and erythrocytes. As the precursor of immune cells, bone 
marrow hematopoietic stem cells have been suggested to be responsible for immune 
dysregulation of T cells in psoriasis. Several recent studies have indicated that abnormal T 
cells may be closely related to anomalous hematopoietic stem cells (HSCs) determined by 
psoriatic hereditary background. In addition to HSCs, aberrant bone marrow mesenchymal 
stem cells have also been demonstrated in patients with psoriasis.  
2. The clinical cue of relationship between psoriasis and bone marrow cells  
Although various exogenous and endogenous factors are believed to activate the immune 
system leading to imbalance of the system and initiation of psoriasis, increasing evidences 
suggest that inherent and intrinsic rather than extrinsic factors are more important in 
psoriasis pathogenesis. These intrinsic factors may be involved in spontaneous T-cell 
activation or proliferation, regulation of cytokine production, hematopoietic cell 
development, and T-cell development in the thymus. Allogeneic bone marrow 
transplantations (BMT) have been reported to either eliminate or aggravate psoriasis. 
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Leukemia patients with psoriasis reportedly have long-term psoriasis remission or 
amelioration. On the other hand, non-psoriatic leukemia patients can develop psoriasis after 
transplanting bone marrow from psoriatic donors. These clinical reports indicate that 
psoriatic immune abnormalities transferred by BMT may have originated from bone 
marrow HSC. 
3. Bone marrow derived hematopoietic stem / progenitor cells from psoriatic 
patients are anomalously proliferative 
Based on the above evidence, many researchers begin to pay close attention to bone marrow 
abnormality of psoriatic patients. In vitro studies have shown that monocytopoietic activity 
is enhanced in psoriasis and functional bone marrow scintigraphy using 99Tcm-labelled 
human serum albumin millimicrospheres has shown hyperplasia of phagocytes in psoriasis. 
Bone marrow, with its rapidly renewing cell populations, is one of the most sensitive tissues 
to various stimulations of exogenous or endogenous factors. Once activated the pathogenic 
peripheral immunocytes in psoriasis and their released soluble factors, such as gamma-
interferon (IFN-γ), interleukin-2 (IL-2), IL-8 and tumor necrosis factor-alpha (TNF-α), may 
influence hematopoietic microenvironment, and even hematopoiesis. In vitro assessment 
using high proliferative potential colony-forming cell (HPP-CFCs) and colony formation 
units (CFU) is used as a surrogate marker of hematopoietic activity and can play a key role 
in linking hematopoiesis to psoriasis. Supernatant of in vitro cultured psoriatic peripheral 
blood mononuclear cells was found to suppress the proliferative activity of normal bone 
marrow HPP-CFCs, CFU-GM (granulocyte-macrophage colony-forming units) and CFU-E 
(erythroid colony-forming units). These results support the hypothesis that aberrant 
psoriatic peripheral immunocytes and cytokines can influence hematopoiesis. 
Recently, besides the influence of aberrant peripheral immunocytes and cytokines, 
researchers began to pay attention to the intrinsic deficiency of psoriatic bone marrow 
hematopoietic cells. Zhang et al. cultured psoriatic bone marrow mononuclear cells in 
methylcellulose semisolid medium and observed their colony formation ability in the 
presence of exogenous cytokine combinations. These studies show a decreased colony 
formation ability of HPP-CFC, CFU-GM but not CFU-E, implying that the proliferative 
activity of HSCs in patients with psoriasis may be intrinsically decreased. They further 
investigated the molecular mechanisms of abnormal proliferative activity of HSCs in 
psoriasis and found that promoter methylation of p15, p16 and p21 genes is significantly 
decreased and transcription levels of these genes are enhanced in ex vivo cultured bone 
marrow HPP-CFCs from psoriatic patients in comparison to those from healthy volunteers. 
The P15, P16 and P21 proteins belong to the INK4 kinase family of cyclin-dependent kinase 
inhibitors and can negatively regulate the cell cycle through competitive inhibition of cyclin-
dependent kinases 2, 4 and 6. Higher expression of these genes may contribute to the low 
proliferative activity of psoriatic hematopoietic cells.  
Expression of Notch receptors and their ligands in hematopoietic system has been widely 
reported, and Notch signaling has been shown to influence hematopoietic cell proliferation 
and differentiation at several stages. The activation of Notch signaling results in 
transcriptional activation of E(spl)/HES genes, which function as negative regulators of cell 
proliferation and differentiation. Moreover, Notch1 and Hes-1 expression is significantly 
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enhanced in psoriatic CD34+ bone marrow cells compared to normal controls. Beside HES 
genes, another transcription factor RUNX-1, which is essential for hematopoietic cell 
development, has long been suspected to be involved in the pathogenesis of psoriasis 
because loss of RUNX1 binding site located between the SLC9A3R1 and NAT9 genes at 
17q25 has been found increased expression in the psoriatic CD34+ cells. These studies 
suggest that the dysfunction of immune cells in psoriatic patients can be traced back to the 
early development of hematopoietic cells. 
4. T cells differentiated from bone marrow derived hematopoietic cells of 
psoriatic patients are functionally different from normal T cells  
Since T cells are derived from bone marrow hematopoietic cells, it is suggested that 
hematopoietic cells are partly relevant to the dysfunction of T cells in psoriasis. To 
demonstrate whether T cells are produced inherently dysfunctional from the immune 
system, Zhang et al. cultured bone marrow CD34+ cells from psoriatic patients and induced 
them to differentiate into T cells and CD4+CD25+ regulatory T cells in vitro. A further 
functional study revealed abnormal characters of these cells compared to normal bone 
marrow derived ones. 
The main hallmark of CD4+CD25+ T cells is their immune regulatory function by interacting 
with effector T cells. Several studies have reported that the CD4+CD25+ T-lymphocyte 
subpopulation in peripheral blood and lesional skin demonstrates a less inhibitory effect on 
effector T cells, leading to accelerated proliferation of pathogenic/effector T-cells in 
autoimmune diseases, especially in psoriasis. Although the proportion of CD4+CD25+ T cells 
and FOXP3 gene expression are comparable in both psoriatic and healthy samples, 
proliferation of psoriatic bone marrow derived CD4+CD25+ T cells is significantly attenuated 
and secretion of cytokines IL-2 and IL-10 is decreased compared to normal controls in 
response to streptococcal superantigen (Strep-A). In particular, CD4+CD25+ T cells 
differentiated from psoriatic CD34+ cells are functionally insufficient to restrain proliferation 
of activated effector T-cells. That is to say, the function of CD4+CD25+ T cells derived from 
psoriatic bone marrow CD34+ cells in vitro is similar to that of peripheral CD4+CD25+ T-
lymphocytes of psoriatic patient in vivo. 
In another study, bone marrow CD34+ hematopoietic cells from psoriatic patients with 
family history were induced into effector T cells and their functions such as in vitro 
proliferation ability, secretion of cytokines IL-4, IL-8 and IFN–γ, and their ability to 
induce human keratinocytes producing C-myc, Bcl-xL, and Ki67 proteins were compared 
with their counterpart from healthy objects. The differentiated T cells from CD34+ cells of 
psoriatic patients showed higher proliferative activity and stronger capacity to secret Th1 
cytokines in response to streptococcal superantigen and could induce expression of C-myc 
and Ki67, but not Bcl-XL in keratinocytes co-cultured with psoriatic differentiated T  
cells. 
These studies show that regulatory as well as effector T cells differentiated from CD34+ cells 
of psoriatic patients, but not normal controls, are functionally similar to those psoriatic 
circulating T cells and suggest that dysfunctional activity of T cells in psoriatic patients can 
be traced back to the early development of hematopoietic cells. 
www.intechopen.com
 Psoriasis 
 
6 
5. The bionomics of psoriatic bone marrow mesenchymal stem cells 
Mesenchymal stem cells, also referred as marrow stromal cells, are another important type 
of stem cells in bone marrow. Cytokines secreted by bone marrow mesenchymal stem cells 
(BMSCs) along with extracellular matrix compose the hematopoietic microenvironment and 
influence hematopoiesis. More than 30 hematopoietic cytokines and growth factors 
including TNF-a, IL-1, IL-6, IL-7, IL-8, IL-10, IL-12, IFN-γ and IL-18 are reportedly secreted 
by BMSCs and many of them could influence immune reaction of peripheral blood. 
Secretion of SCF, granulocyte colony-stimulating factor (G-CSF) and IL-6 is increased in in 
vitro cultured BMSCs from psoriatic patients, while that of IL-1a, IL-1b, IL-3, IL-8, epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF), TNF-a, leukaemia 
inhibitory factor (LIF), hepatocyte growth factor (HGF) and platelet-derived growth factor 
(PDGF) is decreased and the levels of GM-CSF, IL-11 or IL-7 is not altered. Pearson 
correlation analysis demonstrates that those cytokine levels are not correlated with PASI 
scores, indicating that abnormal secretion of cytokines is due to anomaly of BMMSCs 
themselves rather than systemic inflammatory response.   
On the other hand, BMSCs are also characterized by their ability to differentiate into 
multiple mesenchymal lineages, including osteocytes, chondrocytes, adipocytes, endothelial 
cells and skeletal muscle cells under controlled in vitro conditions. Studies have found that 
BMSCs from psoriatic patients have lower proliferative and passage ability and are more 
prone to differentiate into vascular endothelial cells (VEC) compared with those from 
healthy subjects under the same induction conditions. Moreover, this differentiation ability 
is paralleled with the disease severity. In addition, specimens from a patient whose parents 
also have psoriasis could spontaneously differentiate into VECs. Further studies on gene 
expression using RNA sequencing showed a total of 475 genes mostly enriched in 
prostaglandin (PG) and prostanoid metabolic process (unpublished data) are differentially 
expressed in this patient.  
Studies on differential gene expression of BMSCs from 4 psoriatic patients and 3 healthy 
subjects found a total of 1617 genes were differently expressed by more than 2-fold between 
the two groups, among which 324 genes were upregulated and 1293 genes were 
downregulated in psoriatic patients. GO analysis revealed the first five gene-enriched GO 
terms were immune response, inflammatory response, antigen processing and presentation 
of peptide, chemotaxis, and cell adhesion. While the first five highly enriched factor terms 
were positive regulation of CD4+CD25+ alpha-beta regulatory T cell differentiation, 
lipoprotein particle clearance, antigen processing and presentation of peptide, negative 
regulation of peptidase activity, and positive regulation of cholesterol storage (unpublished 
data). These terms have been confirmed to participate in the onset and development of 
psoriasis. 
Taken together, these studies suggest that BMSCs of psoriatic patients are abnormal in 
proliferation, differentiation, passage ability, secretion of multiple cytokines and gene 
expression, and may partly participate in the occurrence and development of psoriasis. In 
other words, psoriasis is a multi-system disease that involves not only the epidermis, but 
also the hematopoietic system, immune system, neuroendocrine system, and so on. With 
continued research, various stem cells may be confirmed to be involved in the generation 
and development of psoriasis. 
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